William E. Duke has sold IVVD and made no open-market buys since Feb 2026

William E. Duke, Jr., M.B.A. is a seasoned finance executive serving as Chief Financial Officer (CFO) of Invivyd, Inc. (NASDAQ: IVVD) since September 1, 2023, and as the company's principal executive officer since May 30, 2024.( At age 52, he is a Certified Public Accountant (CPA) with over 25 years of experience in finance, accounting, and operations within the biotechnology sector.(

Duke holds a B.S. in Business Administration from Stonehill College and an M.B.A. from Bentley University.( His career highlights include prior CFO roles at Apexigen, Inc. (2022–2023, guiding its sale to Pyxis Oncology), Kaleido Biosciences, Inc. (2019–2022, leading multiple financings), and Pulmatrix, Inc. (2015–2019, negotiating the first product partnership and public offerings), as well as senior financial positions at Valeritas, Inc. and Genzyme Corporation (contributing to its sale to Sanofi).( Under his leadership at Invivyd, the company achieved PEMGARDA net product revenue of $13.1 million in Q3 2025 (up 41% YoY) and reduced quarterly net loss from $60.7 million to $10.5 million.( Recently, he received a grant of 625,000 stock options on January 29, 2026, and sold shares worth approximately $63,350 in February 2026.(

Written by Perplexity from public sources.